SHARP: Study of Heart and Renal Protection
principal researchers
Colin Baigent (University of Oxford)
Martin Landray (University of Oxford)
Data custodian
University of Oxford
Funding
Merck/Schering-Plough Pharmaceuticals; Australian National Health and Medical Research Council; British Heart Foundation; UK Medical Research Council
Key Publications
- Design and baseline paper: Am Heart J 2010 Nov;160(5):785-794.e10
- Main results: Lancet 2011 Jun 25;377(9784):2181-92
- Effect on vascular access patency: Clin J Am Soc Nephrol 2014 May;9(5):914-9
- Effect on progression of renal disease: J Am Soc Nephrol 2014 Aug;25(8):1825-33
- Contribution of cause of kidney disease to prognosis in CKD: Am J Kidney Dis 2014 Jul;64(1):40-8
- Impact of CKD stage and CVD on the annual cost of hospital care: BMC Nephrol 2015 Apr 29;16:65
- Impact of educational attainment on health outcomes in moderate to Severe CKD: Am J Kidney Dis. 2016 Jan;67(1):31-9
- Cost-effectiveness for CV prevention in CKD: Am J Kidney Dis 2016 Apr;67(4):576-84
- Smoking and adverse outcomes in patients with CKD: Am J Kidney Dis. 2016 Apr 22. pii: S0272-6386(16)00699-5
- The use of causal diagrams: An example from SHARP. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):546-552
- Prognostic utility of estimated albumin excretion rate in CKD: results from SHARP. Nephrol Dial Transplant 2016 1–8 doi: 10.1093/ndt/gfw396
- Evidence for reverse causality in the association between blood pressure and cardiovascular risk in CKD. Hypertension. 2017 Feb;69(2):314-322
- Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from SHARP: BMC Nephrology 2017 18:147